[go: up one dir, main page]

CL2009000919A1 - Uso de dronedarona o una sal farmaceuticamente aceptable para preparar un medicamento util en la prevencion y/o tratamiento de la hipocalemia. - Google Patents

Uso de dronedarona o una sal farmaceuticamente aceptable para preparar un medicamento util en la prevencion y/o tratamiento de la hipocalemia.

Info

Publication number
CL2009000919A1
CL2009000919A1 CL2009000919A CL2009000919A CL2009000919A1 CL 2009000919 A1 CL2009000919 A1 CL 2009000919A1 CL 2009000919 A CL2009000919 A CL 2009000919A CL 2009000919 A CL2009000919 A CL 2009000919A CL 2009000919 A1 CL2009000919 A1 CL 2009000919A1
Authority
CL
Chile
Prior art keywords
dronedarone
pharmaceutically acceptable
acceptable salt
hypokalemia
prevention
Prior art date
Application number
CL2009000919A
Other languages
English (en)
Inventor
David Van Eickels Martin Radzik
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40001356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2009000919(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of CL2009000919A1 publication Critical patent/CL2009000919A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)

Abstract

Uso de dronedarona o una sal farmacéuticamente aceptable para la preparación de un medicamento útil en la regulación del nivel de potasio en la sangre.
CL2009000919A 2008-04-18 2009-04-16 Uso de dronedarona o una sal farmaceuticamente aceptable para preparar un medicamento util en la prevencion y/o tratamiento de la hipocalemia. CL2009000919A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4599508P 2008-04-18 2008-04-18
FR0803525A FR2930150B1 (fr) 2008-06-24 2008-06-24 Utilisation de la dronedarone pour la preparation d'un medicament destine a reguler le taux de potassium dans le sang

Publications (1)

Publication Number Publication Date
CL2009000919A1 true CL2009000919A1 (es) 2010-04-09

Family

ID=40001356

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009000919A CL2009000919A1 (es) 2008-04-18 2009-04-16 Uso de dronedarona o una sal farmaceuticamente aceptable para preparar un medicamento util en la prevencion y/o tratamiento de la hipocalemia.

Country Status (26)

Country Link
US (1) US20110124724A1 (es)
EP (1) EP2280702A2 (es)
JP (1) JP2011518147A (es)
KR (1) KR20100135814A (es)
CN (1) CN102065857A (es)
AR (1) AR072951A1 (es)
AU (1) AU2009252898A1 (es)
BR (1) BRPI0911198A2 (es)
CA (1) CA2721491A1 (es)
CL (1) CL2009000919A1 (es)
CO (1) CO6260065A2 (es)
CR (1) CR11734A (es)
DO (1) DOP2010000300A (es)
EA (1) EA201071209A1 (es)
EC (1) ECSP10010553A (es)
FR (1) FR2930150B1 (es)
IL (1) IL208751A0 (es)
MA (1) MA32356B1 (es)
MX (1) MX2010011400A (es)
NI (1) NI201000173A (es)
PE (1) PE20091777A1 (es)
SV (1) SV2010003701A (es)
TW (1) TW200946108A (es)
UY (1) UY31768A (es)
WO (1) WO2009144551A2 (es)
ZA (1) ZA201007391B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2930149B1 (fr) * 2008-04-17 2011-02-18 Sanofi Aventis Association de dronedarone avec au moins un diuretique, son application en therapeutique
EA025017B1 (ru) * 2008-04-17 2016-11-30 Санофи-Авентис Способ лечения пациентов с историей фибрилляции предсердий или трепетания предсердий, или существующими фибрилляцией предсердий или трепетанием предсердий, предотвращающий госпитализацию в кардиологическое отделение
FR2930150B1 (fr) * 2008-06-24 2011-01-14 Sanofi Aventis Utilisation de la dronedarone pour la preparation d'un medicament destine a reguler le taux de potassium dans le sang
EP2116239A1 (en) * 2008-04-29 2009-11-11 Sanofi-Aventis Method for managing the risks associated with an increase in serum creatinine during dronedarone treatment
US8602215B2 (en) 2010-06-30 2013-12-10 Sanofi Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation
WO2013024411A1 (en) 2011-08-12 2013-02-21 Lupin Limited Co-milled formulation of dronedarone
BR112014028706B1 (pt) * 2012-05-22 2023-01-10 Sanofi Formulação de dronedarona e associação para uso em leishmaniose
TWI732489B (zh) * 2020-03-17 2021-07-01 國防醫學院 應用心電圖快速偵測鉀離子異常之方法及其系統

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4988513A (en) * 1990-01-09 1991-01-29 Monsanto Company Method of treating hypokalemia
US20080234337A1 (en) * 2004-08-10 2008-09-25 Ono Pharmaceutical Co., Ltd. Preventive and/or Remedy for Hyperkalemia Containing Ep4 Agonist
US20070248564A1 (en) * 2006-04-25 2007-10-25 Roxane Laboratories, Inc. Formulation of sodium polystyrene sulfonate suspension for the treatment of hyperkalemia
FR2930148A1 (fr) * 2008-04-17 2009-10-23 Sanofi Aventis Sa Utilisation de la dronedarone pour la preparation d'un medicament destine a la prevention de l'hospitalisation cardiovasculaire ou de la mortalite
FR2930149B1 (fr) * 2008-04-17 2011-02-18 Sanofi Aventis Association de dronedarone avec au moins un diuretique, son application en therapeutique
FR2930150B1 (fr) * 2008-06-24 2011-01-14 Sanofi Aventis Utilisation de la dronedarone pour la preparation d'un medicament destine a reguler le taux de potassium dans le sang

Also Published As

Publication number Publication date
MX2010011400A (es) 2010-11-12
EP2280702A2 (en) 2011-02-09
JP2011518147A (ja) 2011-06-23
ECSP10010553A (es) 2010-11-30
FR2930150B1 (fr) 2011-01-14
DOP2010000300A (es) 2010-11-15
AR072951A1 (es) 2010-10-06
EA201071209A1 (ru) 2011-04-29
BRPI0911198A2 (pt) 2015-10-13
WO2009144551A3 (en) 2010-01-14
TW200946108A (en) 2009-11-16
CR11734A (es) 2010-12-09
PE20091777A1 (es) 2009-12-04
ZA201007391B (en) 2012-01-25
CA2721491A1 (en) 2009-12-03
IL208751A0 (en) 2010-12-30
US20110124724A1 (en) 2011-05-26
NI201000173A (es) 2011-07-20
CO6260065A2 (es) 2011-03-22
SV2010003701A (es) 2011-01-31
MA32356B1 (fr) 2011-06-01
KR20100135814A (ko) 2010-12-27
WO2009144551A2 (en) 2009-12-03
FR2930150A1 (fr) 2009-10-23
AU2009252898A1 (en) 2009-12-03
UY31768A (es) 2009-12-14
CN102065857A (zh) 2011-05-18

Similar Documents

Publication Publication Date Title
CL2009000919A1 (es) Uso de dronedarona o una sal farmaceuticamente aceptable para preparar un medicamento util en la prevencion y/o tratamiento de la hipocalemia.
CL2012002326A1 (es) Uso de una combinación de por lo menos un agente quimioterapéutico y una cantidad efectiva de un anticuerpo anti-vegf (factor de crecimiento endotelial vascular), porque sirve para preparar un medicamento útil en el tratamiento de cáncer ovárico; y su kit para tratar el cáncer ovárico sin tratamiento anterior en una paciente humana.
BR112013003677A2 (pt) uso de agente farmacologicamente ativo e forma de dosagem farmacêutica
CL2015003022A1 (es) Uso de empagliflozina en la preparacion de un medicamento util en el tratamiento de la enfermedad renal cronica
CL2015002941A1 (es) Usos terapéuticos de empaglifozina
EA201390060A1 (ru) Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний
MA38399A1 (fr) Formulation sous forme de comprimé, utile pour traiter l'insuffisance cardiaque aiguë et l'insuffisance cardiaque chronique
GT200800250A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
UA109650C2 (xx) Біс-арилзв'язані арилтриазолони та їх застосування
EA201291336A1 (ru) Замещенные 5-фтор-1н-пиразолопиридины и их применение
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
LT2013018A (lt) Farmacinė kompozicija, skirta gydyti diabetą ir metabolinius sutrikimus
BRPI0908124A2 (pt) Composto, ativador de glucoquinase, composição farmacêutica, uso de um composto ou sal farmacologicamente aceitavél do mesmo, e, métodos de ativação da glucoquinase, e para tratar e/ou prevenir uma doença
ES2446643R1 (es) Composiciones farmacéuticas combinadas y su uso para preparar un medicamento destinado al tratamiento del vértigo, la cinetosis y la distonía vegetativa-vascular
CO6660486A2 (es) Composición tópica famacéutica o cosmética útil para el tratamiento de enfermedades o condiciones que cursan con un déficit de la maduración de la envoltura córnea
UA114699C2 (uk) Комбінована фармацевтична композиція та методи лікування захворювань або станів, пов'язаних з серцево-судинною системою
PA8806501A1 (es) Triazolotriazinas y triazolopirazinas y su uso
TR201900240T4 (tr) Gece idrara çıkışları azaltmak için desmopresin.
UY31887A (es) Uso de dronedarona para la preparación de un medicamento para uso en la prevención de la cardioversión
CO6460763A2 (es) Métodos y formulaciones ectoparasiticidas
CR20110674A (es) Otamixaban para el tratamiento de pacientes con alteración renal y de edad avanzada con infarto de miocardio sin elevación del ST
UA109944U (uk) Фармацевтична композиція для зниження рівня n-оксиду триметиламіну
TR201901012T4 (tr) Arteriosklerozun tedavisinde nor-safra asitlerinin kullanımı.
BR112012011231A2 (pt) novo tratamento da inflamação sistêmica de baixo grau
CL2009000551A1 (es) Uso de 2-[4-(7-etil-5h-pirrolo[2,3-b]pirazin-6-il)-fenil]-propan-2-ol, o una sal farmaceuticamente aceptable del mismo, para tratar un trastorno relacionado con los ojos como la degeneracion macular, retinopatia diabetica o edema macular diabetico y composicion farmaceutica que comprende a dicho compuesto.